APA (7th ed.) Citation

Li, H., Zhao, W., Li, C., Shen, H., Li, M., Wang, C., . . . Li, J. (2024). The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study. Thoracic Cancer, 15(32), 2327. https://doi.org/10.1111/1759-7714.15455

Chicago Style (17th ed.) Citation

Li, Hongxin, et al. "The Efficacy and Safety of a Novel PD‐1/CTLA‐4 Bispecific Antibody Cadonilimab (AK104) in Advanced Non‐small cell Lung Cancer: A Multicenter Retrospective Observational Study." Thoracic Cancer 15, no. 32 (2024): 2327. https://doi.org/10.1111/1759-7714.15455.

MLA (9th ed.) Citation

Li, Hongxin, et al. "The Efficacy and Safety of a Novel PD‐1/CTLA‐4 Bispecific Antibody Cadonilimab (AK104) in Advanced Non‐small cell Lung Cancer: A Multicenter Retrospective Observational Study." Thoracic Cancer, vol. 15, no. 32, 2024, p. 2327, https://doi.org/10.1111/1759-7714.15455.